TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: Implications for fusion status anddsb repair

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5202-5209

  Pra, Alan Dal ^a,b   Lalonde, Emilie ^a,c   Sykes, Jenna ^a   Warde, Fiona ^a,b   Ishkanian, Adrian ^a,b   Meng, Alice ^a   Maloff, Chad ^d   Srigley, John ^f   Joshua, Anthony M ^a   Petrovics, Gyorgy ^g   Van Der Kwast, Theodorus ^a   Evans, Andrew ^a   Milosevic, Michael ^a,b   Saad, Fred ^h   Collins, Colin ^e   Squire, Jeremy ⁱ   Lam, Wan ^d   Bismar, Tarek A ^j   Boutros, Paul C ^a,c   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e VANCOUVER PROSTATE CENTRE   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ QUEEN S UNIVERSITY   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DNA; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DNA DETERMINATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ERYTHROBLAST TRANSFORMATION SPECIFIC GENE; FOLLOW UP; GENE; GENE FUSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE GUIDED RADIOTHERAPY; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; TISSUE MICROARRAY; TRANSMEMBRANE PROTEASE SERINE 2 GENE; TREATMENT OUTCOME;

COHORT STUDIES; COMPARATIVE GENOMIC HYBRIDIZATION; DNA REPAIR; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84884580486     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1049     Document Type: Article

References (48)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
2. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 2009;106:12465-70.
3. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-tomesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-45.
4. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008;27:5348-53.
5. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011;29:3659-68.
6. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008;21:1451-60.
7. Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011;459:441-7.
8. Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A. Clinical potential of the ERGoncoprotein in prostate cancer. Nat Rev Urol 2012;9:131-7.
9. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
10. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:1081-7.
11. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediaterisk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 2005;104:891-905.
12. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012;109 Suppl 1:22-9.
13. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
14. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-5.
15. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 2008;99:314-20.
16. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM, Tillmans L, et al. Gene panel model predictive of outcome in men at highrisk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008;26:3930-6.
17. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-6.
18. Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer 2012;48:538-46.
19. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-88.
20. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:1497-509.
21. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
22. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010;42:668-75.
23. Swanson TA, Krueger SA, Galoforo S, Thibodeau BJ, Martinez AA, Wilson GD, et al. TMPRSS2/ERG fusion gene expression alters chemoand radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate. 2011 Mar. 10. [Epub ahead of print].
24. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19:664-78.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
26. Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res 2012;18:308-16.
27. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
28. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982;8:1981-97.
29. Mok G, Glicksman R, Sykes J, Bayley A, Chung P, Bristow R, et al. Short term hormone therapy and dose escalated radiation for localized prostate cancer: a randomized phase III study. Radiol Oncol 2012;105:273-382.
30. Ishkanian AS, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol 2010;49:888-94.
31. Jhavar S, Corbishley CM, Dearnaley D, Fisher C, Falconer A, Parker C, et al. Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer 2005;93:478-82.
32. Fleiss J. Measuring Nominal Scale Agreement among many raters. Psychol Bull 1971;76:378-82.
33. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
34. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
35. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
36. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, et al. The ability of biomarkers to predict systemic progression in men with highrisk prostate cancer treated surgically is dependent on ERG status. Cancer Res 2010;70:8994-9002.
37. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
38. Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 2010;20:217-22.
39. Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012;118:4053-62.
40. Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, et al. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate 2003;55:299-307.
41. Kollermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 2008;54:1314-23.
42. Minner S, Gartner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 2013;26:106-16.
43. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, et al. Three-color FISH analysis of TMPRSS2/ERGfusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-9.
44. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
45. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12:590-8.
46. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
47. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013;27:683-98.
48. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012;2:1134-49.